In addition to renin-angiotensin system (RAS) inhibitors, sodium-glucose cotransporter-2 inhibitors (SGLT2is), finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA) and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), have more recently been shown to reduce DKD progression and are considered the standard of care [4,5]. Here, GLP1R is linked to diabetic kidney disease.